Mikael Dolsten

Biography

The WRD group contains all Pfizer research units, including Oncology, Cardiovascular & Metabolic Disease, Neuroscience, Inflammation & Immunology, Vaccines, Rare Disease, as well as the Centers for Therapeutic Innovation (CTI). Mikael, also, has worldwide responsibility for Pfizer’s groups in safety, regulatory and external R&D innovation, in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development. Prior to joining Pfizer in 2009, Mikael was President of Wyeth Research, where he led scientists across the U.S., Europe and Asia. Mikael earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden, where he was appointed Adjunct Professor in Tumor Immunology. He is a fellow of the New York Academy of Medicine. Mikael serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors. He is a member of the Board of Karyopharm Pharmaceuticals and an industry member of the Government-University-Industry Research Roundtable (GUIRR) Council. In addition, Mikael was recently elected as Foreign Member of The Royal Swedish Academy of Engineering Sciences. Mikael is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology.  

Research Interest

He is a fellow of the New York Academy of Medicine. Mikael serves on the Science and Regulatory Executive Committee of The Pharmaceutical Research and Manufacturers of America (PhRMA) and the PhRMA Foundation Board of Directors